Here’s what you need to know.
1. In the first quarter of 2018, Stryker’s shares declined 7.6 percent. Zacks Consensus Estimate puts each share around $7.82, a 0.1 percent drop.
2. Stryker has been struggling since the fourth quarter of 2017 when the company’s adjusted gross margin fell flat year-over-year at 66.4 percent.
3. Stryker’s spine business also experienced supply issues. The company expects supply issues may remain until later this year.
4. Currently, Zacks gives Stryker shares a sell rating. It noted the company’s debt is now up to $7.2 billion.
More articles on devices and implants:
‘Microjoint’ may postpone hip replacements by a decade or more: 4 insights
Dr. Michael Hisey to present findings from Zimmer Biomet Mobi-C post-hoc analysis — 5 highlights
Medtronic taps new VP of global clinical research and analytics: 4 highlights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
